Among breast cancer molecular subtypes, Luminal breast cancer (positive hormone receptor molecular subtype) is responsible for approximately 70% of all breast cancer cases, which justifies the need for novel therapeutic approaches against this tumor type [3]. Here, NR4A1 is linked to breast carcinoma.